| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A clinician’s guide to biosimilars in oncology
|
Rugo, Hope S.
|
|
2016
|
46 |
C |
p. 73-79
7 p.
|
artikel
|
| 2 |
Balancing treatment efficacy, toxicity and complication risk in elderly patients with metastatic renal cell carcinoma
|
van den Brom, R.R.H.
|
|
2016
|
46 |
C |
p. 63-72
10 p.
|
artikel
|
| 3 |
Central nervous system involvement in breast cancer patients: Is the therapeutic landscape changing too slowly?
|
Fontanella, Caterina
|
|
2016
|
46 |
C |
p. 80-88
9 p.
|
artikel
|
| 4 |
Editorial Board
|
|
|
2016
|
46 |
C |
p. IFC-
1 p.
|
artikel
|
| 5 |
Hormone Receptor/Human Epidermal Growth Factor Receptor 2-positive breast cancer: Where we are now and where we are going
|
Schettini, Francesco
|
|
2016
|
46 |
C |
p. 20-26
7 p.
|
artikel
|
| 6 |
How low should we go: A systematic review and meta-analysis of the impact of restrictive red blood cell transfusion strategies in oncology
|
Prescott, Lauren S.
|
|
2016
|
46 |
C |
p. 1-8
8 p.
|
artikel
|
| 7 |
Prognostic value of biochemical response to neoadjuvant androgen deprivation before external beam radiotherapy for prostate cancer: A systematic review of the literature
|
Zilli, Thomas
|
|
2016
|
46 |
C |
p. 35-41
7 p.
|
artikel
|
| 8 |
Targeting the fibroblast growth factor receptor family in cancer
|
Hallinan, Niamh
|
|
2016
|
46 |
C |
p. 51-62
12 p.
|
artikel
|
| 9 |
The immune system and hormone-receptor positive breast cancer: Is it really a dead end?
|
Dieci, Maria Vittoria
|
|
2016
|
46 |
C |
p. 9-19
11 p.
|
artikel
|
| 10 |
The use of circulating tumor cells in guiding treatment decisions for patients with metastatic castration-resistant prostate cancer
|
Onstenk, Wendy
|
|
2016
|
46 |
C |
p. 42-50
9 p.
|
artikel
|
| 11 |
Thymic malignancies: Moving forward with new systemic treatments
|
Remon, J.
|
|
2016
|
46 |
C |
p. 27-34
8 p.
|
artikel
|
Tijdschrift beschrijving